Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
Funding Agency:
- National Institutes of Health
This FOA seeks to encourage quantitative and physical scientists to work with biomedical researchers to catalyze the use of bioengineering approaches for their potential to open new areas of biomedical investigation. Although engineering applications submitted to the EBRG and other related announcements are often perceived as risky, experience shows that engineering training to anticipate errors, analyze what can go wrong, and to use both established and new principles to fix these issues do serve to manage most risks. The EBRG, more so than related bioengineering announcements for mid-level and final developmental and translational stages, does have the risks of feasibility tests, early development, and gathering of preliminary data. Program controls these acceptable risks by limiting total direct cost funds to $275,000 divided across two years. Therefore, EBRG applicants are encouraged to explain the significance of the proposed work, why potential impact outweighs risks, anticipate difficulties and discuss possible workarounds. Projects may include but are not limited to assessing the feasibility of a novel tool for clinical intervention, exploring new approaches to characterizing and modeling complex biological systems, improving and integrating existing technologies to provide a breakthrough in unsolved biomedical problems, or establishing preliminary evidence for a new, perhaps transformative bioengineering approach that challenges accepted paradigms.
The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
February 16, 2022, June 16, 2022, October 16, 2022
Miguel R. Ossandon, Ph.D., National Cancer Institute (NCI), Telephone: 240-276-5714
Email: ossandom@mail.nih.gov